Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Feb;79(3-4):637–639. doi: 10.1038/sj.bjc.6690100

Role of dexamethasone dosage in combination with 5-HT3 antagonists for prophylaxis of acute chemotherapy-induced nausea and vomiting

K Münstedt 1, H Müller 1, E Blauth-Eckmeyer 2, K Stenger 1, M Zygmunt 1, H Vahrson 1
PMCID: PMC2362432  PMID: 10027342

Abstract

Dexamethasone (20 mg) or its equivalent in combination with 5-HT3 antagonists appears to be the gold-standard dose for antiemetic prophylaxis. Additional to concerns about the use of corticosteroids with respect to enhanced tumour growth or impaired killing of the tumour cells, there is evidence that high-dosage dexamethasone impairs the control of delayed nausea and emesis, whereas lower doses appear more beneficial. To come closer to the most adequate dose, we started a prospective, single-blind, randomized trial investigating additional dosage of 8 or 20 mg dexamethasone to tropisetron (Navoban), a 5-HT3 receptor antagonist, in cis-platinum-containing chemotherapy. After an interim analysis of 121 courses of chemotherapy in 69 patients, we have been unable to detect major differences between both treatment alternatives. High-dose dexamethasone (20 mg) had no advantage over medium-dose dexamethasone with respect to objective and subjective parameters of acute and delayed nausea and vomiting. In relation to concerns about the use of corticosteroids in non-haematological cancer chemotherapy, we suggest that 8 mg or its equivalent should be used in combination with 5-HT3 antagonists until further research proves otherwise. © 1999 Cancer Research Campaign

Keywords: nausea, emesis, vomiting, corticosteroid, dexamethasone

Full Text

The Full Text of this article is available as a PDF (80.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Carmichael J., Bessell E. M., Harris A. L., Hutcheon A. W., Dawes P. J., Daniels S., Bessel E. M. Comparison of granisetron alone and granisetron plus dexamethasone in the prophylaxis of cytotoxic-induced emesis. Br J Cancer. 1994 Dec;70(6):1161–1164. doi: 10.1038/bjc.1994.465. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Fredrikson M., Hursti T., Fürst C. J., Steineck G., Börjeson S., Wikblom M., Peterson C. Nausea in cancer chemotherapy is inversely related to urinary cortisol excretion. Br J Cancer. 1992 May;65(5):779–780. doi: 10.1038/bjc.1992.165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Haid M. Steroid antiemesis may be harmful. N Engl J Med. 1981 May 14;304(20):1237–1237. doi: 10.1056/NEJM198105143042015. [DOI] [PubMed] [Google Scholar]
  4. Hursti T. J., Fredrikson M., Steineck G., Börjeson S., Fürst C. J., Peterson C. Endogenous cortisol exerts antiemetic effect similar to that of exogenous corticosteroids. Br J Cancer. 1993 Jul;68(1):112–114. doi: 10.1038/bjc.1993.295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Livrea P., Trojano M., Simone I. L., Zimatore G. B., Logroscino G. C., Pisicchio L., Lojacono G., Colella R., Ceci A. Acute changes in blood-CSF barrier permselectivity to serum proteins after intrathecal methotrexate and CNS irradiation. J Neurol. 1985;231(6):336–339. doi: 10.1007/BF00313712. [DOI] [PubMed] [Google Scholar]
  6. Peterson C., Hursti T. J., Börjeson S., Avall-Lundqvist E., Fredrikson M., Fürst C. J., Lomberg H., Steineck G. Single high-dose dexamethasone improves the effect of ondansetron on acute chemotherapy-induced nausea and vomiting but impairs the control of delayed symptoms. Support Care Cancer. 1996 Nov;4(6):440–446. doi: 10.1007/BF01880642. [DOI] [PubMed] [Google Scholar]
  7. Powell C. B., Mutch D. G., Kao M. S., Kao J. W., Perry D. L., Westphale E., Collins J. L. Dexamethasone used as an antiemetic in chemotherapy protocols inhibits natural cytotoxic (NC) cell activity. Cancer. 1990 Feb 1;65(3):466–472. doi: 10.1002/1097-0142(19900201)65:3<466::aid-cncr2820650315>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  8. SHERLOCK P., HARTMANN W. H. Adrenal steroids and the pattern of metastases of breast cancer. JAMA. 1962 Jul 28;181:313–317. doi: 10.1001/jama.1962.03050300033007. [DOI] [PubMed] [Google Scholar]
  9. Stephens S. H., Silvey V. L., Wheeler R. H. A randomized, double-blind comparison of the antiemetic effect of metoclopramide and lorazepam with or without dexamethasone in patients receiving high-dose cisplatin. Cancer. 1990 Aug 1;66(3):443–446. doi: 10.1002/1097-0142(19900801)66:3<443::aid-cncr2820660307>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  10. Young S. N. Mechanism of decline in rat brain 5-hydroxytryptamine after induction of liver tryptophan pyrrolase by hydrocortisone: roles of tryptophan catabolism and kynurenine synthesis. Br J Pharmacol. 1981 Nov;74(3):695–700. doi: 10.1111/j.1476-5381.1981.tb10480.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. de Haes J. C., van Knippenberg F. C., Neijt J. P. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer. 1990 Dec;62(6):1034–1038. doi: 10.1038/bjc.1990.434. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES